Last $28.70 USD
Change Today +0.31 / 1.09%
Volume 869.9K
MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$27.89
Previous Close
$28.39
Day High
$28.91
Day Low
$27.60
52 Week High
01/28/14 - $37.27
52 Week Low
10/14/14 - $19.92
Market Cap
1.9B
Average Volume 10 Days
1.6M
EPS TTM
$-0.21
Shares Outstanding
65.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

571 Employees
Last Reported Date: 03/3/14
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MDCO) Key Developments

The Medicines Company Revises Earnings Guidance for the Year 2014

The Medicines Company revised earnings guidance for the year 2014. For the year, the company expects net revenue for 2014 will remain within the range of its previously announced guidance of $720 million to $735 million, but expects it to be at the lower end of that range.

The Medicines Company Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 07:30 AM

The Medicines Company Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Clive A. Meanwell, Chairman and Chief Executive Officer.

The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China

The Medicines Company and SciClone Pharmaceuticals announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company: ANGIOMAX (bivalirudin) for Injection, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. A Phase 3 registration trial was completed in China and is currently under review by the China Food and Drug Administration (CFDA) for marketing approval. CLEVIPREX (clevidipine) Injectable Emulsion, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable. The clinical trial application (CTA) for China was filed in 2013. Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market (excluding Hong Kong and Macau). SciClone has also agreed to assist in the China registration process for both products. Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include the following additional payments to The Medicines Company: an upfront payment; a product support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $28.70 USD +0.31

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.66 USD -0.22
CryoLife Inc $11.75 USD -0.09
Eli Lilly & Co $71.73 USD 0.00
GlaxoSmithKline PLC 1,487 GBp +3.00
Medicure Inc C$1.47 CAD 0.00
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.